PROKIDNEY CP (PROK)
(Real Time Quote from BATS)
$2.31 USD
+0.19 (8.96%)
Updated Apr 29, 2024 03:55 PM ET
After-Market: $2.30 -0.01 (-0.43%) 4:10 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for ProKidney Corp falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 363 | 490 | 0 | 0 | -99,999 |
Receivables | 1 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 10 | 14 | 1 | 0 | NA |
Total Current Assets | 374 | 505 | 1 | 0 | NA |
Net Property & Equipment | 42 | 11 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 250 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 421 | 518 | 251 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 5 | 3 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 18 | 7 | 2 | 0 | NA |
Income Taxes Payable | 1 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 25 | 11 | 2 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 0 | 258 | 0 | NA |
Minority Interest (Liabilities) | 1,495 | 1,602 | 0 | 0 | NA |
Total Liabilities | 1,524 | 1,615 | 260 | 0 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 36 | 7 | 0 | 0 | NA |
Retained Earnings | -1,140 | -1,104 | -8 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | -1,103 | -1,097 | -8 | 0 | NA |
Total Liabilities & Shareholder's Equity | 421 | 518 | 251 | 0 | NA |
Total Common Equity | -1,103 | -1,097 | -8 | 0 | 0 |
Shares Outstanding | 228.10 | 25.60 | 25.60 | NA | NA |
Book Value Per Share | -4.84 | -42.84 | -0.33 | 0.00 | 0.00 |
Fiscal Year End for ProKidney Corp falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 363 | 396 | 446 | 464 |
Receivables | NA | 1 | 1 | 8 | 5 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 10 | 9 | 12 | 11 |
Total Current Assets | NA | 374 | 406 | 466 | 480 |
Net Property & Equipment | NA | 42 | 43 | 15 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 421 | 452 | 484 | 495 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 4 | 3 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 18 | 15 | 21 | 7 |
Income Taxes Payable | NA | 1 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 25 | 21 | 25 | 11 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 1,495 | 1,521 | 1,779 | 2,082 |
Total Liabilities | NA | 1,524 | 1,544 | 1,806 | 2,097 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 36 | 41 | 31 | 22 |
Retained Earnings | NA | -1,140 | -1,134 | -1,353 | -1,623 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -1,103 | -1,093 | -1,322 | -1,602 |
Total Liabilities & Shareholder's Equity | NA | 421 | 452 | 484 | 495 |
Total Common Equity | 0 | -1,103 | -1,093 | -1,322 | -1,602 |
Shares Outstanding | 229.30 | 228.10 | 235.40 | 235.10 | 234.90 |
Book Value Per Share | 0.00 | -4.84 | -4.64 | -5.62 | -6.82 |